早期预警及辅助手段在通过疫苗控制香港流感方面的作用。
The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.
作者信息
Hilleman M R
出版信息
Bull World Health Organ. 1969;41(3):623-8.
Abstract
The major antigenic changes in influenza A virus that occur at 10-year intervals reduce the effectiveness of existing vaccines and pose a problem for the control of pandemics by vaccination. These difficulties may be obviated in two ways. First, by detecting the emergence of a new variant sufficiently ahead of its general spread for it to be possible to produce a corresponding vaccine in good time; the World Health Organization is widely depended upon for this early warning. Secondly, by the improvement of existing vaccines to increase and broaden their antigenicity; here, their modification by, for instance, adjuvant 65 may contribute significantly.
摘要
甲型流感病毒每10年发生的主要抗原变化会降低现有疫苗的效力，并给通过接种疫苗控制大流行带来问题。这些困难可以通过两种方式消除。第一，在新变种普遍传播之前足够早地检测到其出现，以便能够及时生产相应的疫苗；世界卫生组织在很大程度上依赖于此进行早期预警。第二，通过改进现有疫苗以增强和拓宽其抗原性；在这里，例如用佐剂65对其进行修饰可能会有很大帮助。
相似文献
1
The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.早期预警及辅助手段在通过疫苗控制香港流感方面的作用。
Bull World Health Organ. 1969;41(3):623-8.
2
The threat and prospects for control of an influenza pandemic.控制流感大流行的威胁与前景
Expert Rev Vaccines. 2004 Feb;3(1):35-42. doi: 10.1586/14760584.3.1.35.
3
Protection against Hong Kong influneza by adjuvant vaccine containing A2-Ann Arbor-67.含A2-安阿伯-67佐剂疫苗对香港流感的防护作用。
Bull World Health Organ. 1969;41(3):562-3.
4
Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011.第五届诱导广谱和持久免疫应答流感疫苗会议报告，世界卫生组织，日内瓦，2011 年 11 月 16-17 日。
Vaccine. 2012 Oct 19;30(47):6612-22. doi: 10.1016/j.vaccine.2012.08.073. Epub 2012 Sep 11.
5
Epidemiology and control of influenza.流感的流行病学与防控
Natl Med J India. 2003 May-Jun;16(3):143-9.
6
Update: influenza activity--United States and worldwide, 2002-03 season, and composition of the 2003-04 influenza vaccine.最新消息：2002 - 2003年流感季节美国及全球流感活动情况，以及2003 - 2004年流感疫苗的成分
MMWR Morb Mortal Wkly Rep. 2003 Jun 6;52(22):516-21.
7
Production and testing in the USA of influenza virus vaccine made from the Hong Kong variant in 1968-69.1968 - 1969年在美国生产和测试由香港变种制成的流感病毒疫苗。
Bull World Health Organ. 1969;41(3):495-6.
8
New vaccine approaches for seasonal and pandemic influenza.针对季节性流感和大流行性流感的新型疫苗研发方法。
Vaccine. 2008 Nov 18;26(49):6232-6. doi: 10.1016/j.vaccine.2008.07.022. Epub 2008 Jul 30.
9
[Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].[首款针对高致病性甲型禽流感（H5N1）病毒的人类疫苗注册：相关考量]
Ned Tijdschr Geneeskd. 2008 Sep 27;152(39):2113-5.
引用本文的文献
1
Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.1968 年大流感后的五十年流感 A(H3N2)
Am J Public Health. 2020 May;110(5):669-676. doi: 10.2105/AJPH.2019.305557.
本文引用的文献
1
NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 2. SHORT-TERM ANIMAL TOXICITY TESTS.新型可代谢的人用免疫佐剂。2. 短期动物毒性试验。
Proc Soc Exp Biol Med. 1964 Jun;116:523-30. doi: 10.3181/00379727-116-29296.
2
NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. I. DEVELOPMENT AND ANIMAL IMMUNE RESPONSE.新型可代谢的人用免疫佐剂。I. 研发与动物免疫反应。
Proc Soc Exp Biol Med. 1964 Jun;116:516-23. doi: 10.3181/00379727-116-29295.
3
NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 3. EFFICACY AND TOXICITY STUDIES IN MAN.新型可代谢的人用免疫佐剂。3. 人体疗效和毒性研究。
N Engl J Med. 1964 Sep 3;271:479-87. doi: 10.1056/NEJM196409032711001.
4
New metabolizable immunologic adjuvant for human use. 6. Disposition of radioactivity after administration of labelled vaccine to the rat.
Proc Soc Exp Biol Med. 1967 Feb;124(2):500-3. doi: 10.3181/00379727-124-31774.
5
New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65.新型可代谢的人用免疫佐剂。5. 65号佐剂中高纯度流感病毒疫苗的评估。
N Engl J Med. 1967 Jan 12;276(2):78-84. doi: 10.1056/NEJM196701122760203.
6
New metabolizable immunologic adjuvant for human use. 4. Development of highly purified influenza virus vaccine in adjuvant 65.新型可代谢人用免疫佐剂。4. 65佐剂中高纯度流感病毒疫苗的研发。
Proc Soc Exp Biol Med. 1966 Dec;123(3):778-82. doi: 10.3181/00379727-123-31601.
7
Antibody response in man to Hong Kong influenza following 1967 formula influenza vaccine in adjuvant 65.1967年配方流感疫苗加佐剂65后人体对香港流感的抗体反应。
Proc Soc Exp Biol Med. 1969 Jun;131(2):501-6. doi: 10.3181/00379727-131-33911.
8
Critical appraisal of emulsified oil adjuvants applied to viral vaccines.应用于病毒疫苗的乳化油佐剂的批判性评价
Prog Med Virol. 1966;8:131-82.
9
Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65.佐剂65中合成双链RNA对流感病毒疫苗抗体反应的超增强作用。
Proc Soc Exp Biol Med. 1969 Jul;131(3):809-17. doi: 10.3181/00379727-131-33983.
10
New metabolizable immunologic adjuvant for human use. 8. Chronic toxicity and teratogenic tests.新型可代谢的人用免疫佐剂。8. 慢性毒性和致畸试验。
Proc Soc Exp Biol Med. 1968 Jul;128(3):699-708. doi: 10.3181/00379727-128-33104.
Zotero 插件